Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wanbury Limited ( (IN:WANBURY) ) just unveiled an announcement.
Wanbury Limited has started commercial production of a key high-potency anaesthetic API at its Tanuku facility in Andhra Pradesh, a milestone that marks the operationalisation of its new multi-purpose intermediate block. The company expects this launch, together with planned production of four additional high-value APIs (in antidiabetic, anticoagulant, antitussive and antidepressant segments) by March 2026, to generate incremental revenues of about Rs 100 crore in Q4 FY2025-26 and FY2026-27, strengthening its API portfolio and positioning it to capture robust global demand in a market estimated at over Rs 5,000 crore.
More about Wanbury Limited
Wanbury Limited is a Mumbai-based pharmaceutical company with a strong presence in domestic and global API markets and branded formulations. The company focuses on high-value active pharmaceutical ingredients, targeting therapeutic areas such as anaesthetics, antidiabetics, anticoagulants, antitussives, and antidepressants, and is expanding its manufacturing footprint through state-of-the-art facilities like its Tanuku plant in Andhra Pradesh.
Average Trading Volume: 5,064
Technical Sentiment Signal: Hold
Current Market Cap: 6.18B INR
For a thorough assessment of WANBURY stock, go to TipRanks’ Stock Analysis page.